{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:49:43Z","timestamp":1788922183515,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["F31DA059236"],"award-info":[{"award-number":["F31DA059236"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA053123"],"award-info":[{"award-number":["UG3DA053123"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA053123"],"award-info":[{"award-number":["UG3DA053123"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA053123"],"award-info":[{"award-number":["UG3DA053123"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA053123"],"award-info":[{"award-number":["UG3DA053123"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA053123"],"award-info":[{"award-number":["UG3DA053123"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA053123"],"award-info":[{"award-number":["UG3DA053123"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA053123"],"award-info":[{"award-number":["UG3DA053123"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA053123"],"award-info":[{"award-number":["UG3DA053123"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA053123"],"award-info":[{"award-number":["UG3DA053123"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA053123"],"award-info":[{"award-number":["UG3DA053123"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001449"],"award-info":[{"award-number":["UL1TR001449"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dedicated Health Research Funds from the University of New Mexico School of Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01105-0","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T09:25:17Z","timestamp":1743153917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Two doses of Q\u03b2 virus like particle vaccines elicit protective antibodies against heroin and fentanyl"],"prefix":"10.1038","volume":"10","author":[{"given":"Isabella G.","family":"Romano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"Johnson-Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan B.","family":"Core","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andzoa N.","family":"Jamus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Brackeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Blough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhakar","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Staats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Wetsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Chackerian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Frietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"1105_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","volume":"70","author":"CL Mattson","year":"2021","unstructured":"Mattson, C. L. et al. Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013\u20132019. MMWR Morb. Mortal. Wkly. Rep. 70, 202\u2013207 (2021).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"1105_CR2","first-page":"43","volume":"34","author":"EA Gardner","year":"2022","unstructured":"Gardner, E. A., McGrath, S. A., Dowling, D. & Bai, D. The opioid crisis: prevalence and markets of opioids. Forensic Sci. Rev. 34, 43\u201370 (2022).","journal-title":"Forensic Sci. Rev."},{"key":"1105_CR3","unstructured":"Drug Overdose Deaths- NIDA. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates."},{"key":"1105_CR4","unstructured":"CDC, National Center for Health Statistics, Office of Communication. U.S. Overdose Deaths In 2021 Increased Half as Much as in 2020\u2014But Are Still Up 15%. cdc.gov https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2022\/202205.htm."},{"key":"1105_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/383819a0","volume":"383","author":"HW Matthes","year":"1996","unstructured":"Matthes, H. W. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383, 819\u2013823 (1996).","journal-title":"Nature"},{"key":"1105_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/2049463720911986","volume":"14","author":"A James","year":"2020","unstructured":"James, A. & Williams, J. Basic opioid pharmacology\u2014an update. Br. J. Pain. 14, 115\u2013121 (2020).","journal-title":"Br. J. Pain."},{"key":"1105_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.7326\/M18-1397","volume":"169","author":"ND Volkow","year":"2018","unstructured":"Volkow, N. D. & Wargo, E. M. Overdose prevention through medical treatment of opioid use disorders. Ann. Intern Med. 169, 190 (2018).","journal-title":"Ann. Intern Med."},{"key":"1105_CR8","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow, N. D., Frieden, T. R., Hyde, P. S. & Cha, S. S. Medication-assisted therapies\u2014tackling the opioid-overdose epidemic. N. Engl. J. Med. 370, 2063\u20132066 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1105_CR9","first-page":"117822182211038","volume":"16","author":"J Dickson-Gomez","year":"2022","unstructured":"Dickson-Gomez, J. et al. \u201cYou\u2019re Not Supposed to be on it Forever\u201d: medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids. Subst. Abus. 16, 117822182211038 (2022).","journal-title":"Subst. Abus."},{"key":"1105_CR10","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","volume":"56","author":"EF Madden","year":"2021","unstructured":"Madden, E. F., Prevedel, S., Light, T. & Sulzer, S. H. Intervention stigma toward medications for opioid use disorder: a systematic review. Subst. Use Misuse 56, 2181\u20132201 (2021).","journal-title":"Subst. Use Misuse"},{"key":"1105_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle, M. R. et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann. Intern. Med. 169, 137 (2018).","journal-title":"Ann. Intern. Med."},{"key":"1105_CR12","doi-asserted-by":"publisher","first-page":"662","DOI":"10.7326\/0003-4819-148-9-200805060-00006","volume":"148","author":"LE Sullivan","year":"2008","unstructured":"Sullivan, L. E. & Fiellin, D. A. Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann. Intern. Med. 148, 662 (2008).","journal-title":"Ann. Intern. Med."},{"key":"1105_CR13","unstructured":"SAMHSA Medications for Opioid Use Disorder. https:\/\/store.samhsa.gov\/sites\/default\/files\/SAMHSA_Digital_Download\/PEP21-02-01-002.pdf."},{"key":"1105_CR14","doi-asserted-by":"publisher","first-page":"112585","DOI":"10.1016\/j.socscimed.2019.112585","volume":"242","author":"A Yamamoto","year":"2019","unstructured":"Yamamoto, A. et al. Association between homelessness and opioid overdose and opioid-related hospital admissions\/emergency department visits. Soc. Sci. Med. 242, 112585 (2019).","journal-title":"Soc. Sci. Med."},{"key":"1105_CR15","doi-asserted-by":"publisher","unstructured":"Bateman, J. T., Saunders, S. E. & Levitt, E. S. Understanding and countering opioid\u2010induced respiratory depression. Br. J. Pharmacol. bph.15580 https:\/\/doi.org\/10.1111\/bph.15580 (2021).","DOI":"10.1111\/bph.15580"},{"key":"1105_CR16","unstructured":"Eliza Wheeler, T., Stephen, J., Michael K. G., Peter J. D., Centers for Disease Control and Prevention (CDC). Opioid overdose prevention programs providing naloxone to laypersons\u2014United States, 2014. MMWR Morb Mortal Wkly Rep. 64, 631-635 (2015)."},{"key":"1105_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMsr1706626","volume":"377","author":"ND Volkow","year":"2017","unstructured":"Volkow, N. D. & Collins, F. S. The role of science in addressing the opioid crisis. N. Engl. J. Med. 377, 391\u2013394 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1105_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1001\/jama.2018.8826","volume":"320","author":"FS Collins","year":"2018","unstructured":"Collins, F. S., Koroshetz, W. J. & Volkow, N. D. Helping to end addiction over the long-term: the research plan for the NIH HEAL initiative. JAMA 320, 129 (2018).","journal-title":"JAMA"},{"key":"1105_CR19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1124\/jpet.120.000014","volume":"374","author":"MD Raleigh","year":"2020","unstructured":"Raleigh, M. D., Accetturo, C. & Pravetoni, M. Combining a candidate vaccine for opioid use disorders with extended-release naltrexone increases protection against oxycodone-induced behavioral effects and toxicity. J. Pharm. Exp. Ther. 374, 392\u2013403 (2020).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1105_CR20","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.bmcl.2017.12.043","volume":"28","author":"A Kimishima","year":"2018","unstructured":"Kimishima, A., Olson, M. E. & Janda, K. D. Investigations into the efficacy of multi-component cocaine vaccines. Bioorg. Med. Chem. Lett. 28, 2779\u20132783 (2018).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1105_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.intimp.2016.03.028","volume":"35","author":"MW Stevens","year":"2016","unstructured":"Stevens, M. W., Gunnell, M. G., Tawney, R. & Owens, S. M. Optimization of a methamphetamine conjugate vaccine for antibody production in mice. Int. Immunopharmacol. 35, 137\u2013141 (2016).","journal-title":"Int. Immunopharmacol."},{"key":"1105_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.drugalcdep.2014.04.003","volume":"140","author":"TR Kosten","year":"2014","unstructured":"Kosten, T. R. et al. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend. 140, 42\u201347 (2014).","journal-title":"Drug Alcohol Depend."},{"key":"1105_CR23","doi-asserted-by":"publisher","first-page":"e2547","DOI":"10.1371\/journal.pone.0002547","volume":"3","author":"J Cornuz","year":"2008","unstructured":"Cornuz, J. et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 3, e2547 (2008).","journal-title":"PLoS One"},{"key":"1105_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/clpt.2010.317","volume":"89","author":"DK Hatsukami","year":"2011","unstructured":"Hatsukami, D. K. et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin. Pharm. Ther. 89, 392\u2013399 (2011).","journal-title":"Clin. Pharm. Ther."},{"key":"1105_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/252708a0","volume":"252","author":"KF Bonese","year":"1974","unstructured":"Bonese, K. F., Wainer, B. H., Fitch, F. W., Rothberg, R. M. & Schuster, C. R. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 252, 708\u2013710 (1974).","journal-title":"Nature"},{"key":"1105_CR26","doi-asserted-by":"publisher","first-page":"107662","DOI":"10.1016\/j.neuropharm.2019.06.001","volume":"158","author":"M Pravetoni","year":"2019","unstructured":"Pravetoni, M. & Comer, S. D. Development of vaccines to treat opioid use disorders and reduce incidence of overdose. Neuropharmacology 158, 107662 (2019).","journal-title":"Neuropharmacology"},{"key":"1105_CR27","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1016\/j.vaccine.2014.07.085","volume":"32","author":"CR Alving","year":"2014","unstructured":"Alving, C. R., Matyas, G. R., Torres, O., Jalah, R. & Beck, Z. Adjuvants for vaccines to drugs of abuse and addiction. Vaccine 32, 5382\u20135389 (2014).","journal-title":"Vaccine"},{"key":"1105_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2011.281","volume":"91","author":"XY Shen","year":"2012","unstructured":"Shen, X. Y., Orson, F. M. & Kosten, T. R. Vaccines against drug abuse. Clin. Pharm. Ther. 91, 60\u201370 (2012).","journal-title":"Clin. Pharm. Ther."},{"key":"1105_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.6b00977","volume":"12","author":"A Kimishima","year":"2017","unstructured":"Kimishima, A., Wenthur, C. J., Zhou, B. & Janda, K. D. An advance in prescription opioid vaccines: overdose mortality reduction and extraordinary alteration of drug half-life. ACS Chem. Biol. 12, 36\u201340 (2017).","journal-title":"ACS Chem. Biol."},{"key":"1105_CR30","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1016\/j.vaccine.2022.03.053","volume":"40","author":"FA Hamid","year":"2022","unstructured":"Hamid, F. A. et al. Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder. Vaccine 40, 3244\u20133252 (2022).","journal-title":"Vaccine"},{"key":"1105_CR31","doi-asserted-by":"publisher","first-page":"8601","DOI":"10.1021\/jacs.7b03334","volume":"139","author":"PT Bremer","year":"2017","unstructured":"Bremer, P. T. et al. Development of a clinically viable heroin vaccine. J. Am. Chem. Soc. 139, 8601\u20138611 (2017).","journal-title":"J. Am. Chem. Soc."},{"key":"1105_CR32","doi-asserted-by":"publisher","first-page":"13294","DOI":"10.1021\/jacs.0c05219","volume":"142","author":"TF Belz","year":"2020","unstructured":"Belz, T. F. et al. Enhancement of a heroin vaccine through hapten deuteration. J. Am. Chem. Soc. 142, 13294\u201313298 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"1105_CR33","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.1016\/j.vaccine.2019.05.061","volume":"37","author":"CS Hwang","year":"2019","unstructured":"Hwang, C. S. et al. Heroin vaccine: using titer, affinity, and antinociception as metrics when examining sex and strain differences. Vaccine 37, 4155\u20134163 (2019).","journal-title":"Vaccine"},{"key":"1105_CR34","doi-asserted-by":"publisher","first-page":"583077","DOI":"10.3389\/fimmu.2020.583077","volume":"11","author":"M Brisse","year":"2020","unstructured":"Brisse, M., Vrba, S. M., Kirk, N., Liang, Y. & Ly, H. Emerging concepts and technologies in vaccine development. Front. Immunol. 11, 583077 (2020).","journal-title":"Front. Immunol."},{"key":"1105_CR35","doi-asserted-by":"publisher","first-page":"16584","DOI":"10.1021\/acsomega.2c00820","volume":"7","author":"C Baehr","year":"2022","unstructured":"Baehr, C. et al. Preclinical efficacy and selectivity of vaccines targeting fentanyl, alfentanil, sufentanil, and acetylfentanyl in rats. ACS Omega 7, 16584\u201316592 (2022).","journal-title":"ACS Omega"},{"key":"1105_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00329-0","volume":"6","author":"AE Stone","year":"2021","unstructured":"Stone, A. E. et al. Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge. NPJ Vaccin. 6, 69 (2021).","journal-title":"NPJ Vaccin."},{"key":"1105_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1021\/acsptsci.1c00260","volume":"5","author":"B Crouse","year":"2022","unstructured":"Crouse, B. et al. Efficacy and selectivity of monovalent and bivalent vaccination strategies to protect against exposure to carfentanil, fentanyl, and their mixtures in rats. ACS Pharmacol. Transl. Sci. 5, 331\u2013343 (2022).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"1105_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","volume":"18","author":"KM Frietze","year":"2016","unstructured":"Frietze, K. M., Peabody, D. S. & Chackerian, B. Engineering virus-like particles as vaccine platforms. Curr. Opin. Virol. 18, 44\u201349 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"1105_CR39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/JCI11849","volume":"108","author":"B Chackerian","year":"2001","unstructured":"Chackerian, B., Lowy, D. R. & Schiller, J. T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Investig. 108, 415\u2013423 (2001).","journal-title":"J. Clin. Investig."},{"key":"1105_CR40","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/vaccines10060875","volume":"10","author":"AL Collar","year":"2022","unstructured":"Collar, A. L., Linville, A. C., Core, S. B. & Frietze, K. M. Epitope-based vaccines against the chlamydia trachomatis major outer membrane protein variable domain 4 elicit protection in mice. Vaccines 10, 875 (2022).","journal-title":"Vaccines"},{"key":"1105_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00457-1","volume":"7","author":"L Jel\u00ednkov\u00e1","year":"2022","unstructured":"Jel\u00ednkov\u00e1, L. et al. A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model. NPJ Vaccin. 7, 34 (2022).","journal-title":"NPJ Vaccin."},{"key":"1105_CR42","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3390\/vaccines9070726","volume":"9","author":"NL Warner","year":"2021","unstructured":"Warner, N. L. & Frietze, K. M. Development of bacteriophage virus-like particle vaccines displaying conserved epitopes of dengue virus non-structural protein 1. Vaccines 9, 726 (2021).","journal-title":"Vaccines"},{"key":"1105_CR43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3390\/vaccines10020227","volume":"10","author":"AL Tornesello","year":"2022","unstructured":"Tornesello, A. L., Tagliamonte, M., Buonaguro, F. M., Tornesello, M. L. & Buonaguro, L. Virus-like particles as preventive and therapeutic cancer vaccines. Vaccines 10, 227 (2022).","journal-title":"Vaccines"},{"key":"1105_CR44","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.vaccine.2023.12.077","volume":"42","author":"IG Romano","year":"2024","unstructured":"Romano, I. G. et al. A bacteriophage virus-like particle vaccine against oxycodone elicits high-titer and long-lasting antibodies that sequester drug in the blood. Vaccine 42, 471\u2013480 (2024).","journal-title":"Vaccine"},{"key":"1105_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0118-4","volume":"4","author":"NM Maphis","year":"2019","unstructured":"Maphis, N. M. et al. Q\u00df Virus-like particle-based vaccine induces robust immunity and protects against tauopathy. NPJ Vaccin. 4, 26 (2019).","journal-title":"NPJ Vaccin."},{"key":"1105_CR46","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3390\/ph14080764","volume":"14","author":"DS Peabody","year":"2021","unstructured":"Peabody, D. S., Peabody, J., Bradfute, S. B. & Chackerian, B. RNA phage VLP-based vaccine platforms. Pharmaceuticals 14, 764 (2021).","journal-title":"Pharmaceuticals"},{"key":"1105_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","volume":"19","author":"S Nooraei","year":"2021","unstructured":"Nooraei, S. et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnol. 19, 59 (2021).","journal-title":"J. Nanobiotechnol."},{"key":"1105_CR48","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1021\/acs.biomac.1c00443","volume":"22","author":"ML Martino","year":"2021","unstructured":"Martino, M. L., Crooke, S. N., Manchester, M. & Finn, M. G. Single-point mutations in Q\u03b2 virus-like particles change binding to cells. Biomacromolecules 22, 3332\u20133341 (2021).","journal-title":"Biomacromolecules"},{"key":"1105_CR49","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0969-2126(96)00060-3","volume":"4","author":"R Golmohammadi","year":"1996","unstructured":"Golmohammadi, R., Fridborg, K., Bundule, M., Valeg\u00e5rd, K. & Liljas, L. The crystal structure of bacteriophage Q beta at 3.5 A resolution. Structure 4, 543\u2013554 (1996).","journal-title":"Structure"},{"key":"1105_CR50","doi-asserted-by":"crossref","unstructured":"Selley, D. E. et al. \u03bc Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine 11Abbreviations: 6-MAM, 6-monoacetylmorphine; GTP\u03b3S, guanosine-5\u2032-O-(\u03b3-thio)-triphosphate; DAMGO, [d-Ala2,(NMe)Phe4,Gly5(OH)]enkephalin; M-6-G, morphine-6-\u03b2d-glucuronide; and hMOR-C6, C6 rat glioma cells expressing human \u03bc opioid receptors. Biochem. Pharmacol 62, 447\u2013455 (2001).","DOI":"10.1016\/S0006-2952(01)00689-X"},{"key":"1105_CR51","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/01.ftd.0000211812.27558.6e","volume":"28","author":"HH Maurer","year":"2006","unstructured":"Maurer, H. H., Sauer, C. & Theobald, D. S. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther. Drug Monit. 28, 447\u2013453 (2006).","journal-title":"Ther. Drug Monit."},{"key":"1105_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0014-5793(88)81294-8","volume":"234","author":"GT Bolger","year":"1988","unstructured":"Bolger, G. T., Skolnick, P., Rice, K. C. & Weissman, B. A. Differential regulation of \u03bc-opiate receptors in heroin- and morphine-dependent rats. FEBS Lett. 234, 22\u201326 (1988).","journal-title":"FEBS Lett."},{"key":"1105_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1139\/y86-001","volume":"64","author":"J Sawynok","year":"1986","unstructured":"Sawynok, J. The therapeutic use of heroin: a review of the pharmacological literature. Can. J. Physiol. Pharmacol. 64, 1\u20136 (1986).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"1105_CR54","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1021\/acschemneuro.9b00305","volume":"10","author":"D Perekopskiy","year":"2019","unstructured":"Perekopskiy, D. & Kiyatkin, E. A. 6-Monoacetylmorphine (6-MAM), not morphine, is responsible for the rapid neural effects induced by intravenous heroin. ACS Chem. Neurosci. 10, 3409\u20133414 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"1105_CR55","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bph.12305","volume":"170","author":"A Gott\u00e5s","year":"2013","unstructured":"Gott\u00e5s, A. et al. Levels of heroin and its metabolites in blood and brain extracellular fluid after i.v. heroin administration to freely moving rats: 6-MAM: a predominant metabolite of heroin. Br. J. Pharm. 170, 546\u2013556 (2013).","journal-title":"Br. J. Pharm."},{"key":"1105_CR56","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.117.247049","volume":"365","author":"MD Raleigh","year":"2018","unstructured":"Raleigh, M. D. et al. Opioid dose- and route-dependent efficacy of oxycodone and heroin vaccines in rats. J. Pharm. Exp. Ther. 365, 346\u2013353 (2018).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1105_CR57","doi-asserted-by":"publisher","first-page":"e115696","DOI":"10.1371\/journal.pone.0115696","volume":"9","author":"MD Raleigh","year":"2014","unstructured":"Raleigh, M. D., Pentel, P. R. & LeSage, M. G. Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats. PLoS ONE 9, e115696 (2014).","journal-title":"PLoS ONE"},{"key":"1105_CR58","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","volume":"33","author":"E Crossey","year":"2015","unstructured":"Crossey, E. et al. A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine 33, 5747\u20135755 (2015).","journal-title":"Vaccine"},{"key":"1105_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2018.e01113","volume":"5","author":"K Sato","year":"2019","unstructured":"Sato, K. et al. Efficient protection of mice from influenza A\/H1N1pdm09 virus challenge infection via high avidity serum antibodies induced by booster immunizations with inactivated whole virus vaccine. Heliyon 5, e01113 (2019).","journal-title":"Heliyon"},{"key":"1105_CR60","doi-asserted-by":"crossref","unstructured":"Bautista T. G. et al. The Brainstem Respiratory Network. In: Faingold CL, Blumenfeld H (Eds) Neuronal Networks in Brain Function, CNS Disorders, and Therapeutics. 235\u2013245 (Academic Press, 2014).","DOI":"10.1016\/B978-0-12-415804-7.00018-6"},{"key":"1105_CR61","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s00204-022-03300-7","volume":"96","author":"BA Baldo","year":"2022","unstructured":"Baldo, B. A. & Rose, M. A. Mechanisms of opioid-induced respiratory depression. Arch. Toxicol. 96, 2247\u20132260 (2022).","journal-title":"Arch. Toxicol."},{"key":"1105_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107730","volume":"158","author":"RD Tenney","year":"2019","unstructured":"Tenney, R. D. et al. Vaccine blunts fentanyl potency in male rhesus monkeys. Neuropharmacology 158, 107730 (2019).","journal-title":"Neuropharmacology"},{"key":"1105_CR63","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1021\/acs.bioconjchem.3c00415","volume":"35","author":"F Shafieichaharberoud","year":"2024","unstructured":"Shafieichaharberoud, F. et al. Enhancing protective antibodies against opioids through antigen display on virus-like particles. Bioconjugate Chem. 35, 164\u2013173 (2024).","journal-title":"Bioconjugate Chem."},{"key":"1105_CR64","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1080\/21645515.2016.1212785","volume":"12","author":"M Pravetoni","year":"2016","unstructured":"Pravetoni, M. Biologics to treat substance use disorders: current status and new directions. Hum. Vaccin. Immunother. 12, 3005\u20133019 (2016).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1105_CR65","doi-asserted-by":"publisher","first-page":"11315","DOI":"10.24875\/RIC.23000117","volume":"75","author":"A Hern\u00e1ndez-P\u00e9rez","year":"2023","unstructured":"Hern\u00e1ndez-P\u00e9rez, A. et al. Addiction to tobacco smoking and vaping. RIC 75, 11315 (2023).","journal-title":"RIC"},{"key":"1105_CR66","unstructured":"Oregon State University. Fentanyl Fact Sheet. https:\/\/oregonstate.app.box.com\/s\/7cxt86s4mqfu0miorqo3l7ouzxxvsfvy."},{"key":"1105_CR67","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/clpt.2008.3","volume":"83","author":"N Benowitz","year":"2008","unstructured":"Benowitz, N. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharm. Ther. 83, 531\u2013541 (2008).","journal-title":"Clin. Pharm. Ther."},{"key":"1105_CR68","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/add.15634","volume":"117","author":"EE Loud","year":"2022","unstructured":"Loud, E. E. et al. Addicted to smoking or addicted to nicotine? A focus group study on perceptions of nicotine and addiction among US adult current smokers, former smokers, non\u2010smokers and dual users of cigarettes and e\u2010cigarettes. Addiction 117, 472\u2013481 (2022).","journal-title":"Addiction"},{"key":"1105_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108653","volume":"195","author":"MD Raleigh","year":"2021","unstructured":"Raleigh, M. D. et al. Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder. Neuropharmacology 195, 108653 (2021).","journal-title":"Neuropharmacology"},{"key":"1105_CR70","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1124\/jpet.111.189506","volume":"341","author":"M Pravetoni","year":"2012","unstructured":"Pravetoni, M. et al. An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J. Pharm. Exp. Ther. 341, 225\u2013232 (2012).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1105_CR71","doi-asserted-by":"publisher","first-page":"e2030201","DOI":"10.1001\/jamanetworkopen.2020.30201","volume":"3","author":"SM Bagley","year":"2020","unstructured":"Bagley, S. M. et al. Incidence and characteristics of nonfatal opioid overdose among youths aged 11 to 24 years by sex. JAMA Netw. Open 3, e2030201 (2020).","journal-title":"JAMA Netw. Open"},{"key":"1105_CR72","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3390\/jpm12060907","volume":"12","author":"M Romanescu","year":"2022","unstructured":"Romanescu, M. et al. Sex-related differences in pharmacological response to CNS drugs: a narrative review. JPM 12, 907 (2022).","journal-title":"JPM"},{"key":"1105_CR73","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/00000542-200008000-00034","volume":"93","author":"B Kest","year":"2000","unstructured":"Kest, B., Sarton, E., Dahan, A. & Fisher, D. M. Gender differences in opioid-mediated analgesia. Anesthesiology 93, 539\u2013547 (2000).","journal-title":"Anesthesiology"},{"key":"1105_CR74","doi-asserted-by":"publisher","first-page":"841873","DOI":"10.3389\/fphar.2022.841873","volume":"13","author":"EB Towers","year":"2022","unstructured":"Towers, E. B., Setaro, B. & Lynch, W. J. Sex- and dose-dependent differences in the development of an addiction-like phenotype following extended-access fentanyl self-administration. Front. Pharmacol. 13, 841873 (2022).","journal-title":"Front. Pharmacol."},{"key":"1105_CR75","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1440-1681.2007.04821.x","volume":"35","author":"S Chan","year":"2008","unstructured":"Chan, S., Edwards, S. R., Wyse, B. D. & Smith, M. T. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. Clin. Exp. Pharm. Physiol. 35, 295\u2013302 (2008).","journal-title":"Clin. Exp. Pharm. Physiol."},{"key":"1105_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0161-1","volume":"5","author":"AL St. John","year":"2020","unstructured":"St. John, A. L. et al. Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy. NPJ Vaccin. 5, 12 (2020).","journal-title":"NPJ Vaccin."},{"key":"1105_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00697-9","volume":"8","author":"B Crouse","year":"2023","unstructured":"Crouse, B. et al. A TLR7\/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models. NPJ Vaccin. 8, 107 (2023).","journal-title":"NPJ Vaccin."},{"key":"1105_CR78","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1021\/jm3013745","volume":"56","author":"M Pravetoni","year":"2013","unstructured":"Pravetoni, M. et al. Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J. Med. Chem. 56, 915\u2013923 (2013).","journal-title":"J. Med. Chem."},{"key":"1105_CR79","doi-asserted-by":"publisher","first-page":"e00475","DOI":"10.1128\/JVI.00475-19","volume":"93","author":"DI Jones","year":"2019","unstructured":"Jones, D. I. et al. Optimized mucosal modified vaccinia virus Ankara prime\/soluble gp120 boost HIV vaccination regimen induces antibody responses similar to those of an intramuscular regimen. J. Virol. 93, e00475\u201319 (2019).","journal-title":"J. Virol."},{"key":"1105_CR80","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","volume":"366","author":"BF Haynes","year":"2012","unstructured":"Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275\u20131286 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1105_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2013.11.026","volume":"404","author":"HE Lynch","year":"2014","unstructured":"Lynch, H. E., Stewart, S. M., Kepler, T. B., Sempowski, G. D. & Alam, S. M. Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen. J. Immunol. Methods 404, 1\u201312 (2014).","journal-title":"J. Immunol. Methods"},{"key":"1105_CR82","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-0773.1998.tb01478.x","volume":"83","author":"M G\u00e5rdmark","year":"1998","unstructured":"G\u00e5rdmark, M., H\u00f6glund, A. U. & Hammarlund-Udenaes, M. Aspects on tail-flick, hot-plate and electrical stimulation tests for morphine antinociception. Pharmacol. Toxicol. 83, 252\u2013258 (1998).","journal-title":"Pharmacol. Toxicol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01105-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01105-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01105-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T02:36:04Z","timestamp":1743388564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01105-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1105"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01105-0","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B. Chackerian has equity in Metaphore Biotechnologies. B. Chackerian, S.B. Core, and K.M. Frietze are inventors on patent application 17\/796,368 which covers the vaccines described in this manuscript. All other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}